Latest news with #ASM
Yahoo
36 minutes ago
- Business
- Yahoo
ASM share buyback update June 23 – 27, 2025
Almere, The NetherlandsJune 30, 2025, 5:45 p.m. CET ASM International N.V. (Euronext Amsterdam: ASM) reports the following transactions, conducted under ASM's current share buyback program. Date Repurchased shares Average price Repurchased value June 23, 2025 9,874 € 517.47 € 5,109,461 June 24, 2025 11,169 € 533.12 € 5,954,417 June 25, 2025 10,980 € 545.59 € 5,990,567 Total 32,023 € 532.57 € 17,054,445 These repurchases were made as part of the €150 million share buyback program which started on April 30, 2025. Of the total program, 40.0% has been repurchased. For further details including individual transaction information please visit: About ASM International ASM International N.V., headquartered in Almere, the Netherlands, and its subsidiaries design and manufacture equipment and process solutions to produce semiconductor devices for wafer processing, and have facilities in the United States, Europe, and Asia. ASM International's common stock trades on the Euronext Amsterdam Stock Exchange (symbol: ASM). For more information, visit ASM's website at This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Contact Investor and media relations Victor BareñoT: +31 88 100 8500 E: Investor relations Valentina FantigrossiT: +31 88 100 8502E: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malay Mail
3 days ago
- Science
- Malay Mail
Academy of Sciences Malaysia at 30: A true shaper of our future, or mere commentator? — Ahmad Ibrahim
JUNE 27 — As the Academy of Sciences Malaysia (ASM) marks its 30th anniversary this year, it's worth pausing to ask: has it truly become the change maker it aspired to be? From an inaugural cohort of 50 distinguished Fellows to a current membership exceeding 500, ASM's growth is undeniable. Its ambition to position itself as the nation's foremost science thought leader, however, remains a work in progress — both promising and fraught with challenges. A champion of thought leadership? In its early years, ASM was envisioned as a high-level, non-partisan body providing independent, science-based advice to the government and society. Its founding principles mirrored those of national academies in advanced economies: a sanctuary for scientific intellect, an honest broker in policy deliberations, and a custodian of national scientific direction. To its credit, ASM has produced landmark policy studies, convened dialogues on pressing issues such as water management, energy security, food sustainability, and climate resilience, and provided input for national policies like the 10-10 Malaysian Science, Technology, Innovation, and Economy (MySTIE) Framework. In recent years, ASM's push for circular economy discourse and emphasis on sustainability science are encouraging signs of a body striving to remain relevant in a volatile and rapidly transforming global landscape. Yet, one must ask — has ASM succeeded in embedding itself into the nation's decision-making DNA? Or has it been more of a boutique advisory institution, heard selectively and conveniently by policymakers when alignment suits? The challenges that linger Despite its achievements, ASM faces several structural and operational challenges if it is to claim — and sustain — the mantle of a true change maker. One is about maintaining independence in a politicised environment. The Malaysian policy ecosystem has, for decades, been characterised by the politicisation of expertise. The risk for any government-linked body is the temptation to play it safe. ASM must guard its independence vigorously, ensuring its advice remains evidence-based, candid, and unafraid to challenge the status quo — even when politically inconvenient. Bridging science and society is a challenge. While ASM has been relatively successful in engaging the government, its footprint among the Malaysian public remains modest. In an era where misinformation and pseudoscience spread rapidly, a thought leader must also be a public educator. ASM must broaden its outreach, becoming a household name associated with credible, accessible science communication, especially on controversial issues like climate change, vaccines, and emerging technologies. ASM must invest in storytelling — framing science not as abstract, elite knowledge, but as a lived, daily experience that touches livelihoods, aspirations, and fears of ordinary Malaysians. — Picture by Unsplash/Takashi Miyazaki Funding and talent sustainability continue to be a concern. Sustainable, apolitical funding remains a chronic issue for most academies in developing countries. ASM must diversify its revenue base, perhaps through partnerships, endowments, and commissioned studies, to maintain operational independence and attract top-tier, diverse expertise beyond the conventional academic establishment. Reinventing for the next generation remains an important agenda. The Academy's Fellow demographic still skews towards senior academics, many of whom have spent careers in public universities. While their experience is invaluable, ASM must actively create pathways for young, diverse voices — including social scientists, technologists, entrepreneurs, and civic scientists — to shape national discourse. Many agree ASM should become a convenor of difficult conversations. Moving forward, Malaysia's biggest challenges — from energy transition to artificial intelligence ethics to food security — demand interdisciplinary, cross-sectoral deliberations. ASM is uniquely positioned to convene these difficult, and often contentious, conversations. But it must be prepared to navigate political sensitivities, institutional inertia, and public scepticism. The path forward The time is ripe for ASM to reimagine its role not just as an advisor, but as a national conscience for science, technology, and innovation. Its next chapter should see it adopting a more activist stance: proactively setting national agendas, identifying blind spots in policy, and mobilising scientific communities towards socially inclusive outcomes. ASM must also invest in storytelling — framing science not as abstract, elite knowledge, but as a lived, daily experience that touches livelihoods, aspirations, and fears of ordinary Malaysians. Only then can it earn the trust capital needed to be a genuine change maker. In marking its 30th year, ASM stands at a strategic crossroads. It has history, credibility, and a platform. Whether it evolves into a bold, independent, and people-centred academy, or remains a polite policy appendage, depends on its willingness to embrace discomfort, dissent, and diversity in pursuit of national progress. That, ultimately, will decide if ASM will shape Malaysia's future — or merely comment on it. At the end of the day, ASM must strive to deliver its tagline, Think Science, Celebrate Technology and Inspire Innovation. * Prof Datuk Dr Ahmad Ibrahim is affiliated with the Tan Sri Omar Centre for STI Policy Studies at UCSI University and is an associate fellow at the Ungku Aziz Centre for Development Studies, Universiti Malaya. ** This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Yahoo
6 days ago
- Business
- Yahoo
Zymo Research Unveils MultiOmiX Workstation with Show-Stopping Launch at ASM Microbe 2025
IRVINE, Calif., June 24, 2025 /PRNewswire/ -- Zymo Research stole the spotlight at the American Society for Microbiology (ASM) Microbe 2025 conference with the official debut of the MultiOmiX Workstation, a next-generation platform delivering fully automated, high-throughput microbiome workflows – from sample through NGS-ready libraries. A Dramatic Entrance Draws a Crowd In a bold PR stunt, a tracked remote-controlled model of the MultiOmiX Workstation made a dramatic entrance to the Zymo Research booth, gliding in like an autonomous rover. The reveal drew large crowds, generating buzz around Zymo Research's latest innovation. Attendees were treated to live presentations and technical demos, showcasing the platform's ability to streamline long-standing bottlenecks in sample processing. Demonstrations highlighted the platform's ability to eliminate bottlenecks by enabling simultaneous DNA and RNA purification and automating NGS library preparation for both metagenomic and metatranscriptomic analysis. A Game-Changer for Microbiome Research The MultiOmiX Workstation is a turnkey automated platform built to streamline microbiome workflows, reduce hands-on time, and enhance reproducibility at scale. Designed in collaboration with the Opentrons Labworks FLEX instrument, the workstation combines sample handling, nucleic acid purification, and library preparation into a cohesive turnkey workflow. Simultaneous DNA and RNA purification from the same sample Automated purification and library preparation Processing of up to 96 samples per run Pre-scripted workflows – no coding required Support for both DNA-Seq and RNA-Seq for metagenomic and metatranscriptomic analysis Expert Commentary from Zymo Research & Opentrons "MultiOmiX is the first fully automated, turnkey system for simultaneous DNA and RNA purification from a single sample—combined with dual library prep for 16S and total RNA sequencing. Powered by Zymo's proven chemistries and Opentrons' automation, it's a truly complete multiomic solution for high-throughput microbiome genetic and transcriptomic analysis, maximizing efficiency, reproducibility, and data quality." — Gregory Lee, Director of Automation, Zymo Research "Our collaboration with Zymo Research highlights how open automation can accelerate microbiome research. By integrating Zymo's validated reagents and standardized workflows with Opentrons' flexible automation platforms, we're helping labs streamline complex protocols, improve reproducibility, and scale their studies with confidence. This partnership is about expanding access to high-quality, automated science across the research community." — James Atwood, PhD, Chief Operating Officer, Opentrons Labworks MultiOmiX: Extending Zymo Research's Multiomics Capabilities The MultiOmiX platform embodies Zymo Research's commitment to simplifying the pursuit of scientific discovery by delivering a truly seamless, automated solution for microbiome sample processing—from raw input to NGS-ready output. Incorporating Zymo Research's validated ZymoBIOMICS® reagents and unbiased lysis technology with precision automation, this integration accelerates time-to-result and empowers researchers across clinical, industrial, and academic settings to scale their microbiome and multiomic studies with confidence. By translating decades of microbiome expertise into a turnkey automation platform, Zymo Research is redefining what's possible for labs striving for efficiency, quality, and scientific impact. With the launch of the MultiOmiX Workstation, Zymo Research reaffirms its belief that the beauty of science lies in simplicity and empowering labs of all sizes to accelerate microbiome research with confidence and precision. Learn more about the first turnkey, multiomic, automated solution for microbiome research: Here About Zymo Research Corp. Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges. Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services. In addition to its cutting-edge technologies, Zymo Research is committed to sustainability. By engineering environmentally friendly solutions, the company strives to reduce waste and contribute to a more sustainable future through scientific innovation. For more information, please visit and follow on Facebook, LinkedIn, X (Twitter), and Instagram. View original content to download multimedia: SOURCE Zymo Research Corp. Sign in to access your portfolio
News18
23-06-2025
- Business
- News18
Nifty 50 Rejig Likely: BSE, IndiGo May Enter; IndusInd Bank, Hero MotoCorp On Exit Watch
Last Updated: BSE Ltd, and InterGlobe Aviation—parent company of IndiGo—are likely contenders for inclusion in the Nifty 50 index in the upcoming review BSE Ltd, and InterGlobe Aviation—the parent company of IndiGo—are likely contenders for inclusion in the Nifty 50 index in the upcoming review, according to sources cited by CNBC-TV18. On the other hand, IndusInd Bank and Hero MotoCorp may be removed from the index due to recent underperformance and negative triggers. BSE Ltd, despite being listed only on the NSE, is reportedly eligible for inclusion as it meets the required listing and trading criteria. Its stock has surged nearly 120% from March lows, driven by robust growth in equity derivatives volumes and excitement around the anticipated IPO of NSE. Recently, BSE shares were placed under the Additional Surveillance Measure (ASM) framework due to unusual price and volume activity. IndiGo's parent, InterGlobe Aviation, has seen a 22% rise in its share price over the past six months, supported by strong passenger traffic and market leadership. Brokerage Jefferies has called it a 'unique, strong" franchise, highlighting its dominant 60% domestic market share. As of 12:50 PM, BSE shares were up over 2% at Rs 2,745, while InterGlobe Aviation gained 0.75% to Rs 5,431. IndusInd Bank has underperformed in recent months, falling 11% in six months amid governance concerns, regulatory scrutiny, and questions over derivatives exposure. The stock has also been dropped from the Sensex. At the same time, IndusInd Bank traded 0.4% lower at Rs 837, while Hero MotoCorp was down 2% at Rs 4,256 per share. The Nifty 50 index is reviewed semi-annually, based on data for the six-month periods ending January 31 and July 31. Changes, if any, are implemented in March and September. Eligibility is primarily based on average free-float market capitalisation, which considers only shares available for public trading (excluding promoter and locked-in shares). The upcoming review is expected in August, with changes taking effect in September.
Yahoo
22-06-2025
- Health
- Yahoo
New Data Show Delve Bio's Metagenomic Testing Delivers Broader, Deeper Pathogen Identification Compared to Traditional Testing
Data Presented at the 2025 American Society for Microbiology Microbe Conference BOSTON, June 22, 2025--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at the American Society for Microbiology (ASM) Microbe conference in Los Angeles showing the impact of metagenomic sequencing for transforming infectious disease diagnostics by offering advances compared to traditional microbiological testing. Among the data presented at the meeting is a comparison of Delve's metagenomic cerebrospinal fluid (CSF) test, Delve Detect CSF, compared to a traditional PCR-based meningitis/encephalitis (ME) panel. The study reanalyzed samples from a diverse patient cohort previously tested using the ME panel. The data showed that mNGS can be used in conjunction with microbiological testing to increase diagnostic yield by identifying pathogens that are not detectable with traditional, pathogen-specific panel testing. The inclusion of mNGS tests like Delve Detect, which has a 48-hour turnaround time, can shorten time to diagnosis, enabling clinicians to initiate targeted therapies sooner. "This study showed substantial agreement between Delve Detect and a syndromic PCR panel. But importantly, Delve Detect also identified pathogens that were not included on the PCR panel and would have been missed as causes of a patient's infection if mNGS were not included in the diagnostic workup," said Benjamin Bradley, M.D., Ph.D., medical director of virology and molecular infectious diseases at ARUP Laboratories. "This study supports including mNGS in the diagnostic workup for patients with complex central nervous system infections." The study included 122 samples — 47 positive and 75 negative. Analysis showed that in comparison with the ME panel, Delve Detect CSF demonstrated approximately 10% higher positivity rate (48% vs. 38%), with an additive diagnostic yield of 24%. This added yield included detection of multiple co-infections, 16 unique organisms not included in the ME panel, and positive detections in 19 samples (25%) that were negative by the ME panel. Additionally, in samples that were negative by both tests, Delve Detect CSF showed high agreement (95%) with the ME panel, supporting the negative predictive value of mNGS. The company's full presence at ASM Microbe 2025 includes: Delve's chief medical officer Steve Miller, M.D., Ph.D. hosted A New Era: Metagenomic Sequencing for Comprehensive Pathogen Detection, exploring real world evidence, clinical cases and considerations for laboratory teams implementing mNGS. Presentation of a case report in a feature poster, Using Metagenomic Sequencing to Diagnose a Novel Moraxella CNS Shunt Infection in a Culture-Negative Case Presentation of data comparing the company's mNGS CSF test, Delve Detect, to a widely used, PCR meningitis/encephalitis panel as part of the session Assessing the Clinical Impact of Next-Generation Sequencing: Where Are We Now? "These presentations at ASM highlight the transformation underway in infectious disease diagnostics. Delve Bio's metagenomic sequencing technology enables clinicians to identify the cause of serious central nervous system infections when existing methods do not deliver a diagnosis and speed is critical," said Brad Murray, chief executive officer of Delve Bio. "We're working to make this technology more widely available to neurologists, infectious disease physicians and laboratory teams so they can get patients the answers they need." Conference attendees are also invited to visit Delve Bio at booth #1440 to learn more about the company's metagenomic platform, including Delve Detect and its proprietary bioinformatics platform Delve Decide. Delve Detect is Delve Bio's flagship metagenomic testing service, providing comprehensive pathogen detection with a 48-hour turnaround time after sample receipt and including access to Delve's Clinical Microbial Sequencing Board, an on-call team of infectious disease experts who review results in clinical context. About Delve Bio, Inc. Delve Bio is a metagenomic next-generation sequencing (mNGS) company that empowers laboratories and clinicians with the insights they need to confidently diagnose routine and rare infectious diseases, thereby minimizing the impact of harmful pathogens on humanity. By leveraging its unbiased, pathogen-agnostic mNGS platform, Delve Bio is able to identify a wide range of pathogens with a single test. Founded by world leaders in genomics and infectious disease Drs. Charles Chiu, Joe DeRisi, Michael Wilson, Pardis Sabeti, and Matthew Meyerson, the company is backed by top institutional investors including Perceptive Xontogeny Venture Fund II, Section 32, and GV, along with leading individual investors. For more information, visit View source version on Contacts Company Contact Amy WongSenior Director of Marketing and Business Development, Delve BioEmail: media@ Media Contact Julie McKeough42 North for Delve BioEmail: julie@ Sign in to access your portfolio
